Drug Trial Radar · NCT07562581
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Jun 2029
Study completion Jun 2030
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
Conditions
- Non-small Cell Lung Caner
- KRAS-mutated
- Metastasis
- Previous Treamted
Interventions
luvometinib + anlotinibBiological
Dose A:luvometinib 8mg and anlotinib 8mg; Dose B1:luvometinib 12mg and anlotinib 8mg; Dose B2: luvometinib 8mg and anlotinib 10mg; Dose C: luvometinib 12mg and anlotinib 10mg.
luvometinib + anlotinibBiological
in this part, patients will receive the combined treatment of luvometinib and anlotinib at the recommended doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the objective response rate (ORR) per RECIST v1.1Time frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.